"The combination of Allergan and Pfizer is a highly strategic, value-enhancing transaction that brings together two biopharma powerhouses to change lives for the better," said Mr Saunders. "This bold action is the next chapter in the successful transformation of Allergan allowing us to operate with greater resources at a much bigger scale." Upon closing, the combined company is expected to maintain Allergan's Irish legal domicile – a move which has seen the US-based Pfizer accused of corporate tax avoidance (i.e., tax inversion) by president Obama, among others. Nevertheless, subject to certain conditions, including receipt of regulatory approval in certain jurisdictions such as the US and EU, and the receipt of necessary approvals from Pfizer and Allergan shareholders, the transaction is expected to complete in the second half of 2016. News: Pfizer to buy Allergan in $160 billion deal